PCM
SRPT icon

Prelude Capital Management’s Sarepta Therapeutics SRPT Stock Holding History

Prelude Capital Management’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-1,900
Closed -$324K – 1795
2020
Q4 		$324K Buy
+1,900
New +$282K 0.01% 883
2020
Q3 		– Sell
-300
Closed -$48K – 2313
2020
Q2 		$48K Hold
300
– – ﹤0.01% 1172
2020
Q1 		$29K Hold
300
– – ﹤0.01% 892
2019
Q4 		$39K Sell
300
-15,200
-98% -$1.53M ﹤0.01% 1430
2019
Q3 		$1.17M Buy
15,500
+12,600
+434% +$1.49M 0.05% 297
2019
Q2 		$441K Buy
2,900
+2,600
+867% +$316K 0.02% 529
2019
Q1 		$36K Buy
+300
New +$38.6K ﹤0.01% 1213
2018
Q1 		– Sell
-500
Closed -$28K – 1707
2017
Q4 		$28K Sell
500
-3,500
-88% -$185K ﹤0.01% 1057
2017
Q3 		$181K Buy
4,000
+2,000
+100% +$79.9K 0.02% 686
2017
Q2 		$67K Hold
2,000
– – 0.01% 904
2017
Q1 		$59K Buy
+2,000
New +$61.9K 0.01% 924
2016
Q3 		– Sell
-1,000
Closed -$19K – 1802
2016
Q2 		$19K Buy
+1,000
New +$18.5K ﹤0.01% 1290
2016
Q1 		– Sell
-500
Closed -$19K – 1501
2015
Q4 		$19K Sell
500
-3,900
-89% -$126K ﹤0.01% 1201
2015
Q3 		$141K Sell
4,400
-500
-10% -$17K 0.02% 734
2015
Q2 		$149K Sell
4,900
-7,000
-59% -$143K 0.02% 747
2015
Q1 		$158K Sell
11,900
-5,500
-32% -$73.3K 0.02% 755
2014
Q4 		$252K Sell
17,400
-4,200
-19% -$71.1K 0.04% 557
2014
Q3 		$456K Buy
21,600
+8,100
+60% +$183K 0.06% 402
2014
Q2 		$402K Buy
13,500
+3,200
+31% +$101K 0.05% 463
2014
Q1 		$248K Buy
10,300
+5,800
+129% +$148K 0.03% 652
2013
Q4 		$92K Buy
4,500
+3,400
+309% +$101K 0.02% 871
2013
Q3 		$52K Buy
+1,100
New +$42.4K 0.01% 921

Other funds holding SRPT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Prelude Capital Management's SRPT Position: Q3 2025 in Review

Prelude Capital Management sold out of Sarepta Therapeutics (SRPT) in Q3 2025, closing a stake of 13,135 shares — an estimated $225K sold.

Prelude Capital Management first reported a position in SRPT in Q2 2013 and held it in 32 quarters. The position peaked at $3.82M in Q3 2017. 320 funds tracked by Wall St. Rank hold SRPT as of Q3 2025.

  • Prelude Capital Management reported no remaining Sarepta Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Prelude Capital Management sold 13,135 Sarepta Therapeutics shares in Q3 2025, an estimated $225K.
  • Prelude Capital Management first reported a position in Sarepta Therapeutics in Q2 2013 and held it in 32 quarters.
  • Prelude Capital Management's Sarepta Therapeutics position peaked at $3.82M in Q3 2017.
  • 320 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q3 2025.

Based on Prelude Capital Management's 13F filing for Q3 2025, filed 14 Nov 2025.